Loading...
Market
How many prescriptions for Miplyffa will be written by the end of Q2 2025?
2
Resolution / Starting Odds
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Prescription data from healthcare analytics firms or Zevra Therapeutics' reports
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C, $150 Million Voucher
Sep 20, 2024, 01:40 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, arimoclomol, also known as Miplyffa, for the treatment of Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. This approval marks the first oral medication to receive FDA approval for NPC. In addition, Zevra Therapeutics is now eligible to receive a Priority Review Voucher worth approximately $150 million. The approval was announced on September 20, 2024, ahead of the NDA PDUFA date of September 21, 2024.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%